PALVELLA THERAPEUTICS, INC. (PVLA) earnings date
Mar 31, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 24 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | before open | 35 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Tue, Mar 31, 2026 | before open | 90 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | after close | 41 | 8-K |
| Q2 FY2025 | Thu, Aug 14, 2025 | before open | 45 | 8-K |
| Q1 FY2025 | Thu, May 15, 2025 | before open | 45 | 8-K |
| Q4 FY2024 | Mon, Mar 31, 2025 | before open | 90 | 8-K |
What they guided beta
| Q3 FY2026 | "Presented two posters at Fall Clinical Dermatology 2026 highlighting Phase 3 SELVA participant-reported clinical benefits and treatment satisfaction, as well as low and stable systemic rapamycin exposure over 24 hours, with mean exposure at least 40-fold lower than reported exposure with oral sirolimus." exhibit |
| Q3 FY2026 | "Topline results from LOTU are expected in the second half of 2027." exhibit |
| Q3 FY2026 | "Phase 2 trial initiation expected in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of" exhibit |
| Q2 FY2026 | "The Company remains on track to complete the NDA submission in the second half of 2026." exhibit |
| Q2 FY2026 | "Topline results from LOTU are expected in the second half of 2027." exhibit |
| Q2 FY2026 | "Phase 2 trial initiation expected in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PVLA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PVLA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PVLA/"><img src="https://veritasdata.dev/embed/PVLA.svg" alt="PVLA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PVLA/)
Script
<script async src="https://veritasdata.dev/embed/PVLA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PVLA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.